Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Platelet beta-adrenoceptors.

R Kerry, M C Scrutton

    British Journal of Pharmacology
    |July 1, 1983
    PubMed
    Summary
    This summary is machine-generated.

    Human platelets possess beta-2 adrenoceptors that inhibit aggregation by increasing cyclic AMP. Rat platelets also appear to have beta-2 adrenoceptors, but they do not inhibit aggregation.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Entrustable professional activities for physiotherapists to demonstrate digital health competency: an international delphi study.

    Physiotherapy theory and practice·2025
    Same author

    Adverse effects as a consequence of being the subject of orthopaedic manual therapy training, a worldwide retrospective survey.

    Musculoskeletal science & practice·2017
    Same author

    Spatial 3D distribution of soil organic carbon under different land use types.

    Environmental monitoring and assessment·2017
    Same author

    International framework for examination of the cervical region for potential of Cervical Arterial Dysfunction prior to Orthopaedic Manual Therapy intervention.

    Manual therapy·2014
    Same author

    Revised cardiac risk index and postoperative morbidity after elective orthopaedic surgery.

    British journal of anaesthesia·2011
    Same author

    Relationship Between the Systems Responsible for Uptake of 5-hydroxytryptamine and of Noradrenaline by Human Blood Platelets.

    Platelets·2010
    Same journal

    Glucagon-like peptide-1 improves vascular endothelial dysfunction in hypertensive mice via CREB-driven transcriptional regulation of long non-coding RNA 155383.

    British journal of pharmacology·2026
    Same journal

    The chemokine receptor-like fourth extracellular loop of the apelin receptor differentially regulates apelin and elabela binding and signalling.

    British journal of pharmacology·2026
    Same journal

    Peripheral targets for neuropathic pain.

    British journal of pharmacology·2026
    Same journal

    Therapeutic potential of liver X receptor agonist GW3965 in preserving myelin integrity following traumatic brain injury.

    British journal of pharmacology·2026
    Same journal

    The role of protein arginine methyltransferases in sickle cell-mediated neurovascular impairments in mice.

    British journal of pharmacology·2026
    Same journal

    β-Cyclodextrin inclusion enhances the pro-resolving effects of the annexin A1 mimetic Ac2-26 in a mouse model of antigen-induced arthritis.

    British journal of pharmacology·2026
    See all related articles

    Area of Science:

    • Pharmacology
    • Platelet Biology
    • Adrenergic Signaling

    Background:

    • Isoprenaline inhibits platelet aggregation, a response modulated by adrenergic receptors.
    • The specific subtypes of adrenoceptors involved in platelet function are not fully elucidated.

    Purpose of the Study:

    • To investigate the role of beta-1 and beta-2 adrenoceptors in mediating the inhibitory effects of isoprenaline on human and rat platelet aggregation.
    • To determine the mechanism by which isoprenaline inhibits platelet aggregation, focusing on cyclic AMP levels.

    Main Methods:

    • Assessing the effects of beta-1 and beta-2 adrenoceptor antagonists and agonists on platelet aggregation induced by various agonists.
    • Measuring platelet cyclic adenosine 3',5'-monophosphate (cyclic AMP) levels in response to isoprenaline and other agonists.

    Related Experiment Videos

  • Utilizing adenylate cyclase inhibitors to investigate the role of cyclic AMP in the observed inhibition.

    • Main Results:

    • Beta-2 adrenoceptor antagonists blocked isoprenaline-induced inhibition of human and rat platelet aggregation, while beta-1 antagonists were ineffective.
    • Beta-2 adrenoceptor agonists inhibited human platelet aggregation, but less effectively than isoprenaline, and did not affect rat platelets.
    • Isoprenaline increased human platelet cyclic AMP levels, correlating with the inhibition of aggregation, an effect blocked by adenylate cyclase inhibitors.
    • Rat platelets did not show inhibition of aggregation by beta-1 or beta-2 agonists, though beta-2 agonists blocked isoprenaline's inhibitory effect.

    Conclusions:

    • Human platelets possess functional beta-2 adrenoceptors that inhibit agonist-induced aggregation via elevation of cyclic AMP.
    • The beta-adrenoceptor on rat platelets is also likely the beta-2 subtype, but it does not mediate inhibition of aggregation.
    • These findings highlight species-specific differences in beta-adrenoceptor function on platelets.